Product Pathways - Apoptosis
Phospho-DR6 (Ser562) Antibody #7616
|7616S||100 µl (10 western blots)||---||In Stock||---|
|7616||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat||Endogenous||80||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
Phospho-DR6 (Ser562) Antibody recognizes endogenous levels of DR6 protein only when phosphorylated at Ser562. This antibody may recognize DR6 with dual phosphorylation at Ser562 and Ser565.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser562 of human DR6 protein. Antibodies are purified by protein A and peptide affinity chromatography.
The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases.
DR6, also known as TNFRSF21, is a TNFR family member able to induce apoptosis as well as activation of NF-κB and JNK (3). Expression of DR6 is upregulated by NF-κB signaling (4). DR6 appears to play a critical role in the activation and differentiation of T and B lymphocytes (5,6). In the nervous system β-amyloid precursor protein (APP) activates DR6 to trigger neuronal degeneration (7).
Phospho-DR6 (Ser562) Antibody is directed at a site that was identified at Cell Signaling Technology (CST) using PhosphoScan®, our proprietary LC-MS/MS platform for modification site discovery using an Akt substrate antibody (8). Please visit PhosphoSitePlus®, our modification site knowledgebase, at www.phosphosite.org for more information.
- Nagata, S. (1997) Cell 88, 355-365.
- Thorburn, A. (2004) Cell. Signal. 16, 139-144.
- Pan, G. et al. (1998) FEBS Lett 431, 351-6.
- Kasof, G.M. et al. (2001) Oncogene 20, 7965-75.
- Zhao, H. et al. (2001) J Exp Med 194, 1441-8.
- Schmidt, C.S. et al. (2003) J Exp Med 197, 51-62.
- Nikolaev, A. et al. (2009) Nature 457, 981-9.
- Moritz, A. et al. (2010) Sci Signal 3, ra64.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.